By Capping Out-Of-Pocket Price, Eli Lilly Could Transform Insulin Market

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 59%

United States News News

United States United States Latest News,United States United States Headlines

Eli Lilly To Lower Insulin Prices And Introduce A $35 Out-Of-Pocket Monthly Cap For Commercially Insured And Uninsured Diabetics

which Eli Lilly posted will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products. Apart from this move, the manufacturer stated that as of May 1st it will reduce the list price of an unbranded insulin it sells from $82 to $25 a vial.

It will be interesting to observe whether other insulin-manufacturing companies will follow suit with price reductions. They may have to, as otherwise they could lose a considerable amount of their market share. In addition, it will be intriguing to note how payers and PBMs respond.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in US

United States United States Latest News, United States United States Headlines